tiprankstipranks
Biotech Alert: Searches spiking for these stocks today
The Fly

Biotech Alert: Searches spiking for these stocks today

Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

  • Royalty Pharma (RPRX), 261% surge in interest
  • Navidea Biopharmaceuticals (NAVB), 255% surge in interest
  • Ocugen (OCGN), 2417% surge in interest
  • Aptorum Group (APM), 214% surge in interest
  • Ocular Therapeutics (OCUL), 206% surge in interest

Pipeline and key clinical candidates for these companies:

Royalty Pharma identifies itself as "the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry." Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of "many of the industry’s leading therapies," the company states. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates.

Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. 

Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company’s "breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product," says Ocugen, which adds that it is advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.

Aptorum Group is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology, autoimmune and infectious diseases. Aptorum has completed two phase I clinical trials for its ALS-4 and orphan drug designated SACT-1 small molecule drugs and commercializing its NLS-2 NativusWell nutraceutical. 

Ocular Therapeutix is focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, Dextenza, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI, currently in Phase 1 clinical trials for the treatment of wet AMD and diabetic retinopathy; OTX-TIC, currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI for the chronic treatment of dry eye disease and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials.

Recent news on these stocks:

May 24

In a regulatory filing, Royalty Pharma CEO and chairman Pablo Legorreta disclosed the purchase of 150,000 class A ordinary shares of the company on May 24 at a price of $32.2496 per share.

Ocugen announced the pricing of its underwritten public offering of 30M shares of its common stock for gross proceeds of $16.M, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about May 26, subject to customary closing conditions. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

Hear more from InvestingChannel by signing up for The Spill.


About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.

Keywords: biotech, biotech sector, biotech alert, investingchannel, XBI, SPDR S&P Biotech ETF

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on RPRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles